uploads/2017/11/Revlimid.png

How Celgene’s Revlimid and Pomalyst Are Positioned after 3Q17

By

Updated

Revlimid’s revenue trends

In 3Q17, Celgene’s (CELG) Revlimid generated revenues of $2.1 billion, which reflected ~10.0% growth year-over-year (or YoY) and ~2.0% growth quarter-over-quarter. In 3Q17, Revlimid contributed to ~63.0% of Celgene’s net revenues.

In the US market, Revlimid generated revenues of ~$1.4 billion in 3Q17 compared to ~$1.2 billion in 3Q16. In the US market, Revlimid witnessed 17.9% growth in 3Q17 on a YoY basis.

Article continues below advertisement

Outside the US market, Revlimid generated revenues of $720.0 million in 3Q17 compared to $738.0 million in 3Q16. Outside the US market, Revlimid witnessed a 2.4% decline in 3Q17 on a YoY basis. Revlimid’s price increase and the rise in unit sales due to the treatment duration of patients primarily contributed to the drug’s revenue growth in 3Q17.

The unfavorable impact of smaller Russian tender in 3Q17 compared to 3Q16 led to a modest decline in its international volume growth.

Pomalyst’s revenue trends

In 3Q17, Pomalyst generated revenues of ~$417.0 million, which reflected ~22.0% growth on a YoY basis and ~7.0% growth on a quarter-over-quarter basis. In the US market, Pomalyst generated revenues of ~$268.0 million in 3Q17 compared to $203.0 million in 3Q16. 

In 3Q17, Pomalyst witnessed 32.0% growth on a YoY basis. Outside the US markets, Pomalyst generated revenues of ~$149.0 million in 3Q17 compared to $138.0 million in 3Q16. Outside the US markets, Revlimid witnessed 8.0% growth in 3Q17 on a YoY basis. 

Growth in unit sales in the US market coupled with price increases primarily attributed to the revenue growth of Pomalyst in 3Q17.

In the multiple myeloma market, Revlimid and Pomalyst’s peers include Amgen’s Kyprolis, Johnson & Johnson’s Darzalex, Takeda Pharmaceuticals’ Velcade, Novartis’s Farydak, and Bristol-Myers Squibb’s Empliciti. 

In 3Q17, Amgen’s (AMGN) Kyprolis, Johnson & Johnson’s (JNJ) Darzalex, and Bristol-Myers Squibb’s (BMY) Empliciti reported revenues of around $207.0 million, $317.0 million, and $60.0 million, respectively.

Growth in sales of Revlimid and Pomalyst could boost the iShares NASDAQ Biotechnology ETF (IBB). Celgene comprises ~6.9% of IBB’s total portfolio holdings.

Advertisement

More From Market Realist